CLINICAL TRIAL: TRIAL OF EARLY AGGRESSIVE TREATMENT IN JUVENILE IDIOPATHIC ARTHR

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究希望，在多关节幼年特发性关节炎症状出现后6个月内开始积极治疗，将比目前的治疗方法更有效，在6个月内实现非活动期疾病，12个月临床缓解。治疗A组给予甲氨蝶呤、安慰剂Enbrel和安慰剂强的松龙治疗。治疗B组给予甲氨蝶呤、恩布瑞尔、强的松龙治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The study hopes that starting aggressive therapy within 6 months after the symptoms of polyarticular juvenile idiopathic arthritis starts will be more effective than current treatment in achieving inactive disease by 6 months and clinical remission by 12 months. Treatment group A will receive methotrexate placebo Enbrel and placebo prednisolone. Treatment group B will receive methotrexate, Enbrel and Prednisolone.